Cargando...
COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
PURPOSE: In 2018,Optune (TTF) became available covered by public insurance for patients with glioblastoma,based on the effectiveness of the US EF-14 study (TTF + TMZ (temozolomide) vs. TMZ). There are problems such as use of at least 18 hours a day,behavior restrictions,expensive medical expenses,et...
Gardado en:
| Publicado en: | Neurooncol Adv |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213445/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.203 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|